サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1785841

バイオマーカー臨床フェーズアウトソーシングサービスの世界市場

Biomarker Clinical Phase Outsourcing Services

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
バイオマーカー臨床フェーズアウトソーシングサービスの世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バイオマーカー臨床フェーズアウトソーシングサービスの世界市場は2030年までに287億米ドルに達する見込み

2024年に92億米ドルと推定されるバイオマーカー臨床フェーズアウトソーシングサービスの世界市場は、2024～2030年の分析期間においてCAGR 20.8%で成長し、2030年には287億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである予測バイオマーカーは、CAGR 20.2%を記録し、分析期間終了までに110億米ドルに達すると予測されます。予後バイオマーカー分野の成長率は、分析期間中CAGR 21.9%と推定されます。

米国市場は24億米ドル、中国はCAGR19.7%で成長すると予測

米国のバイオマーカー臨床フェーズアウトソーシングサービス市場は、2024年には24億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに44億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ18.9%と18.1%と予測されています。欧州では、ドイツがCAGR約15.0%で成長すると予測されています。

世界のバイオマーカー臨床フェーズアウトソーシングサービス市場- 主要動向と促進要因のまとめ

なぜバイオマーカー臨床フェーズアウトソーシングサービスの需要が高まっているのか？

精密医療や標的治療の急速な拡大により、バイオマーカーに基づく臨床試験のニーズが大幅に高まり、製薬企業やバイオテクノロジー企業がバイオマーカー開発の主要フェーズをアウトソーシングするようになりました。バイオマーカー臨床フェーズアウトソーシングサービスは、バイオマーカー検証、患者層別化、生物学的分析試験、規制遵守サポートなど、幅広い機能を包含しています。医薬品開発プロセスがより複雑化し、データ駆動型になるにつれ、これらの重要なフェーズを専門の開発業務受託機関（CRO）にアウトソーシングすることは、業務を合理化し、市場投入までの時間を短縮するために不可欠な戦略となりつつあります。さらに、がん、神経変性疾患、心血管疾患などの慢性疾患の流行が拡大していることから、バイオマーカーを活用した診断・治療ソリューションの必要性が高まっています。バイオマーカーは、病気の進行を予測し、治療効果を評価し、副作用を最小限に抑える上で重要な役割を果たすため、最新の臨床試験には欠かせないものとなっています。製薬企業が高度に個別化された治療レジメンの開発に努める中、バイオマーカーサービスのアウトソーシングに対する需要が急増しており、専門的な知識を有するCROのインフラや規制当局への対応能力を活用できるようになっています。

技術の進歩はバイオマーカーアウトソーシングサービスをどのように変革しているか？

技術革新はバイオマーカーアウトソーシングの状況を一変させ、より迅速で正確、かつ費用対効果の高い臨床相試験を可能にしています。ゲノミクス、プロテオミクス、メタボロミクスの進歩により、新規バイオマーカーが発見され、疾患の早期発見や治療モニタリングが向上しています。AIと機械学習はバイオマーカーデータ解析をさらに強化し、研究者が膨大なデータセットから意味のあるパターンと相関関係を特定することを可能にし、患者選択を最適化し、試験の成功率を向上させています。さらに、バイオマーカー解析における次世代シークエンシング（NGS）とデジタルパソロジーの統合は、疾患メカニズムに対するより正確な洞察をもたらしています。これらの技術はコンパニオン診断の効率を向上させ、標的治療の開発を強化しています。さらに、リキッドバイオプシー技術の利用がバイオマーカーに基づく臨床試験で普及しつつあり、低侵襲的な手技によって疾患の進行をリアルタイムでモニタリングできるようになっています。このような技術的進歩がバイオマーカー開発を形成し続けているため、アウトソーシングサービスはますます高度化し、製薬企業やバイオテクノロジー企業により包括的でカスタマイズされたソリューションを提供しています。

バイオマーカー臨床フェーズアウトソーシングサービスの成長を促進する市場動向とは？

バイオマーカーのアウトソーシング市場を形成する最も顕著な動向の一つは、個別化医療への注目の高まりです。ヘルスケアが画一的なアプローチからより個別化された治療戦略へとシフトするにつれ、バイオマーカー主導型の医薬品開発の必要性が高まっています。製薬企業はバイオマーカーのアウトソーシングサービスを活用して、特定の治療法が最も有効であると考えられる患者サブグループを特定する特殊な臨床試験を実施し、治療成績の向上と薬事承認の可能性を高めています。もう一つの重要な市場動向は、分散型臨床試験やバーチャル臨床試験の台頭です。デジタルヘルス技術や遠隔患者モニタリングの進歩により、バイオマーカー研究は従来の臨床環境を超えて拡大しています。CROは、遠隔バイオマーカー収集、AI主導の分析、クラウドベースのデータ管理ソリューションを提供するようになっており、委託臨床試験段階の効率性とアクセシビリティを高めています。さらに、FDAやEMAなどの規制機関はバイオマーカー主導型の医薬品承認を推進しており、製薬企業がバイオマーカーの検証・検査サービスのアウトソーシングに投資することをさらに後押ししています。

バイオマーカー臨床フェーズアウトソーシングサービス市場の主な成長促進要因は？

バイオマーカー臨床フェーズアウトソーシングサービス市場の成長は、臨床試験の複雑化、個別化医療に対する需要の高まり、バイオマーカー調査技術の進歩など、いくつかの要因によってもたらされます。バイオマーカー開発には高いコストとリソースを要するという性質があるため、医薬品パイプラインの最適化と業務負担の軽減を目指す製薬企業にとって、アウトソーシングは魅力的な選択肢となっています。また、臨床試験の世界化も市場拡大に寄与しています。アウトソーシングにより、製薬企業は規制要件を遵守しながら、複数の地域でバイオマーカー研究を実施できるようになるからです。さらに、バイオマーカー研究におけるAIとビッグデータ解析の採用が拡大しており、データ解釈の合理化と臨床試験の効率化が進んでいます。精密医療とバイオマーカー探索の絶え間ない革新に伴い、バイオマーカー臨床段階サービスのアウトソーシング市場は飛躍的な成長が見込まれ、CROは医薬品開発と個別化ヘルスケアの将来において不可欠なパートナーとして位置付けられています。

セグメント

バイオマーカータイプ（予測バイオマーカー、予後バイオマーカー、安全性バイオマーカー、代替エンドポイント）、治療領域（がん治療領域、神経治療領域、循環器治療領域、自己免疫疾患治療領域、その他治療領域）、エンドユーザー（バイオテクノロジー企業エンドユーザー、製薬企業エンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Celerion
  • Charles River Laboratories
  • Clario
  • Eurofins Scientific SE
  • GenScript Biotech Corporation
  • ICON Plc
  • IQVIA
  • Laboratory Corporation of America Holdings
  • NorthEast BioAnalytical Laboratories LLC
  • Parexel International Corporation
  • Proteome Sciences
  • Syneos Health

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29591

Global Biomarker Clinical Phase Outsourcing Services Market to Reach US$28.7 Billion by 2030

The global market for Biomarker Clinical Phase Outsourcing Services estimated at US$9.2 Billion in the year 2024, is expected to reach US$28.7 Billion by 2030, growing at a CAGR of 20.8% over the analysis period 2024-2030. Predictive Biomarkers, one of the segments analyzed in the report, is expected to record a 20.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Prognostic Biomarkers segment is estimated at 21.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 19.7% CAGR

The Biomarker Clinical Phase Outsourcing Services market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 19.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.9% and 18.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global Biomarker Clinical Phase Outsourcing Services Market - Key Trends & Drivers Summarized

Why Is the Demand for Biomarker Clinical Phase Outsourcing Services Rising?

The rapid expansion of precision medicine and targeted therapies has significantly increased the need for biomarker-based clinical trials, leading pharmaceutical and biotechnology companies to outsource key phases of biomarker development. Biomarker clinical phase outsourcing services encompass a wide range of functions, including biomarker validation, patient stratification, bioanalytical testing, and regulatory compliance support. As drug development processes become more complex and data-driven, outsourcing these critical phases to specialized contract research organizations (CROs) is becoming an essential strategy to streamline operations and accelerate time-to-market. Additionally, the growing prevalence of chronic diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions has fueled the need for biomarker-driven diagnostics and therapeutic solutions. Biomarkers play a crucial role in predicting disease progression, assessing treatment responses, and minimizing adverse effects, making them indispensable for modern clinical trials. As pharmaceutical companies strive to develop highly personalized treatment regimens, the demand for outsourced biomarker services is surging, allowing them to leverage the expertise, infrastructure, and regulatory proficiency of specialized CROs.

How Are Technological Advancements Transforming Biomarker Outsourcing Services?

Technological innovations are revolutionizing the biomarker outsourcing landscape, enabling faster, more accurate, and cost-effective clinical phase studies. Advances in genomics, proteomics, and metabolomics have led to the discovery of novel biomarkers, improving early disease detection and therapeutic monitoring. AI and machine learning are further enhancing biomarker data analysis, allowing researchers to identify meaningful patterns and correlations from vast datasets, optimizing patient selection, and improving trial success rates. Moreover, the integration of next-generation sequencing (NGS) and digital pathology in biomarker analysis is providing more precise insights into disease mechanisms. These technologies are improving the efficiency of companion diagnostics and enhancing the development of targeted therapies. Additionally, the use of liquid biopsy techniques is gaining traction in biomarker-based clinical trials, allowing for real-time monitoring of disease progression through minimally invasive procedures. As these technological advancements continue to shape biomarker development, outsourcing services are becoming increasingly sophisticated, offering more comprehensive and tailored solutions for pharmaceutical and biotech companies.

What Market Trends Are Driving the Growth of Biomarker Clinical Phase Outsourcing Services?

One of the most prominent trends shaping the biomarker outsourcing market is the increasing focus on personalized medicine. As healthcare shifts from a one-size-fits-all approach to more individualized treatment strategies, the need for biomarker-driven drug development has intensified. Pharmaceutical firms are leveraging biomarker outsourcing services to conduct specialized clinical trials that identify patient subgroups most likely to benefit from specific therapies, improving treatment outcomes and regulatory approval chances. Another key market trend is the rise of decentralized and virtual clinical trials. With advancements in digital health technologies and remote patient monitoring, biomarker research is expanding beyond traditional clinical settings. CROs are increasingly offering remote biomarker collection, AI-driven analytics, and cloud-based data management solutions, enhancing the efficiency and accessibility of outsourced clinical trial phases. Furthermore, regulatory agencies such as the FDA and EMA are promoting biomarker-driven drug approvals, further encouraging pharmaceutical companies to invest in outsourced biomarker validation and testing services.

What Are the Key Growth Drivers for the Biomarker Clinical Phase Outsourcing Services Market?

The growth in the Biomarker Clinical Phase Outsourcing Services market is driven by several factors, including the increasing complexity of clinical trials, rising demand for personalized medicine, and advancements in biomarker research technologies. The high costs and resource-intensive nature of biomarker development have made outsourcing an attractive option for pharmaceutical companies seeking to optimize their drug pipelines and reduce operational burdens. The globalization of clinical trials is also contributing to market expansion, as outsourcing enables pharmaceutical firms to conduct multi-regional biomarker studies while ensuring compliance with regulatory requirements. Additionally, the growing adoption of AI and big data analytics in biomarker research is streamlining data interpretation and improving clinical trial efficiencies. With continuous innovations in precision medicine and biomarker discovery, the market for outsourced biomarker clinical phase services is expected to witness exponential growth, positioning CROs as indispensable partners in the future of drug development and personalized healthcare.

SCOPE OF STUDY:

The report analyzes the Biomarker Clinical Phase Outsourcing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biomarker Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints); Therapeutic Area (Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area, Other Therapeutic Areas); End-Use (Biotechnology Companies End-Use, Pharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

  • Celerion
  • Charles River Laboratories
  • Clario
  • Eurofins Scientific SE
  • GenScript Biotech Corporation
  • ICON Plc
  • IQVIA
  • Laboratory Corporation of America Holdings
  • NorthEast BioAnalytical Laboratories LLC
  • Parexel International Corporation
  • Proteome Sciences
  • Syneos Health

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biomarker Clinical Phase Outsourcing Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Biomarker-Driven Drug Development Pipelines Throws the Spotlight on Clinical Phase Outsourcing Services
    • Rising Complexity of Multimodal Biomarkers Drives Demand for Specialized Clinical Validation Expertise
    • Increased Use of Companion Diagnostics in Oncology Spurs Outsourcing of Biomarker-Enriched Trials
    • Regulatory Push for Stratified Trial Designs Strengthens Business Case for Biomarker-Driven Patient Segmentation
    • Expansion of Immunotherapy and Precision Medicine Trials Accelerates Need for Outsourced Biomarker Operations
    • Growth in Liquid Biopsy and Non-Invasive Monitoring Platforms Fuels Demand for Flexible Clinical Trial Models
    • OEM Focus on Accelerating Time-to-IND and Time-to-Approval Drives Adoption of Biomarker CRO Partnerships
    • Emergence of Multi-Omic and Digital Biomarkers Expands Technical Capabilities Required From Service Providers
    • Increased Integration of Central Lab and Site Network Services Enhances Operational Continuity in Biomarker Trials
    • Use of AI for Adaptive Trial Design and Endpoint Prediction Supports Outsourced Biomarker Optimization
    • Rise in Real-World Evidence and Post-Market Studies Reinforces Role of Biomarkers in Longitudinal Monitoring
    • Globalization of Multicenter Trials Promotes Outsourcing of Biomarker Logistics and Compliance Management
    • OEM Partnerships With Bioinformatics Firms Enhance Clinical Interpretation of High-Dimensional Biomarker Data
    • Regulatory Harmonization Across FDA, EMA, and PMDA Supports Outsourced Global Biomarker Development
    • Increasing Use of Circulating Tumor DNA and RNA Biomarkers Drives Sample Handling and Data Processing Outsourcing
    • OEM Demand for Centralized Data Platforms and Biomarker Traceability Strengthens Outsourced Model Preference
    • Growth in Rare Disease Trials and Niche Patient Populations Fuels Biomarker-Centric Outsourcing Models
    • OEM Investment in Risk-Based Monitoring and Decentralized Trials Expands Biomarker Data Capture Models
    • Availability of Qualified Biomarker Banks and Retrospective Analysis Services Supports Late-Phase Trial Value
    • Cost-Containment and Operational Efficiency Objectives Drive Long-Term Outsourcing in Biomarker-Enriched Clinical Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Predictive Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Predictive Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Prognostic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Prognostic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Safety Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Safety Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Surrogate Endpoints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Surrogate Endpoints by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Autoimmune Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Autoimmune Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Biomarker Clinical Phase Outsourcing Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Biomarker Clinical Phase Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Biomarker Type - Percentage Breakdown of Value Sales for Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers and Surrogate Endpoints for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Biomarker Clinical Phase Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Biomarker Clinical Phase Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION